Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. for alleged securities fraud affecting investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that defendants made false statements regarding Telix's progress with prostate cancer therapeutic candidates [2]. - It is alleged that the quality of Telix's supply chain and partners was materially overstated by the defendants [2]. - As a result of these misrepresentations, statements about Telix's business, operations, and prospects were deemed materially false and misleading [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. Lawsuit – TLX